REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Primary Objectives:

* To determine the acute and long-term outcomes of redo TAVR for the treatment of BVF affecting TAVs * To determine the factors which are associated with the acute and long-term outcomes of redo TAVR

• Valve Academic Research Consortium (VARC) 3 technical success (at exit from procedure room) [Срок оценки: Time of procedure]
• VARC 3 30-day device success [Срок оценки: 30-Day]
• VARC 3 30-day early safety [Срок оценки: 30-Day]
• Peak and mean invasive gradient post-procedure [Срок оценки: Time of procedure]
• In-hospital clinical outcomes [Срок оценки: Treatment up to 7 days (or until patient is discharged from the hospital if later than 7 days)]
• Clinical outcomes at 30 days, 1-year, and annually thereafter [Срок оценки: 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.]
• Bioprosthetic Valve Dysfunction (BVD) at the final required follow-up visit [Срок оценки: 5 year]
• Bioprosthetic Valve Failure (BVF) at the final required follow-up visit [Срок оценки: Through study completion or Up to 5-years]
• Echocardiographic assessment pre-discharge or at 30 days, 1-year, and annually thereafter [Срок оценки: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.]
• Evaluate coronary accessibility (e.g., commissural alignment, valve to valve alignment, etc.) based on Computed Tomography (CT) at either pre-discharge or 30 days [Срок оценки: Up to 30 days]
• New York Heart Association (NYHA) classification at pre-discharge, 30 days, 1-year, and annually thereafter [Срок оценки: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.]
• KCCQ Quality of life (QoL) assessments at 30 days, 1-year, and annually thereafter [Срок оценки: At 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.]